New Two-Pronged attack on HPV throat cancer shows promise
NCT ID NCT05996523
Summary
This study is testing whether a new HPV vaccine (PRGN-2009) works better when given alongside an immunotherapy drug (pembrolizumab) before patients start their standard cancer treatment. It aims to boost the immune system's attack on the cancer cells. The trial is for adults newly diagnosed with HPV-positive throat cancer and involves a few clinic visits for injections and tests.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OROPHARYNGEAL SQUAMOUS CELL CARCINOMA (SCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.